Product Information

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $0.7351 per EA under NDC 42858060203. Its NADAC has been published 277 times since Aug 4, 2021.

FDA first approved this application on Mar 30, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET

Buprenorphine and Naloxone
$0.7351per EA
DEA Schedule CIII

Strength

8; 2 mg/1; mg/1

NDC

42858060203

Classification

Generic

Dosage Form

TABLET

Route

SUBLINGUAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA205601

FDA Approved

3/30/2020

TE Code

AB

On Market Since

4/13/2020

Pharmacological Classes

Opioid Antagonist
Opioid Antagonists
Partial Opioid Agonist
Partial Opioid Agonists

Price Statistics

The NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has been published 277 times since Aug 4, 2021, and over the history we have for it it has declined 38.4%. The table below summarizes its recorded NADAC range and movement.

Current price$0.7351 per EA
All-time high$1.1932 (Aug 11, 2021)
All-time low$0.6322 (Jul 22, 2026)
52-week high$0.7351
52-week low$0.6322
Median price$0.9288
Average price$0.8740
Largest weekly change+29.6% (Aug 21, 2024)
Weeks tracked277
Tracking sinceAug 4, 2021

Price History

1W

+2.5%

1M

+10.9%

3M

+15.2%

6M

+8.4%

1Y

+4.6%

3Y

-20.9%

5Y

-26.3%

All

-38.4%

Generic Alternatives

The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET, manufactured by Rhodes Pharmaceuticals L.P., is $0.7351 per EA (NDC 42858060203), effective Nov 18, 2026.

How has the price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET changed over time?

Over the history we have for it, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has declined 38.4%. It has been tracked across 277 weekly CMS publications since Aug 4, 2021.

What are the highest and lowest recorded NADAC prices for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

Since Aug 4, 2021, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has ranged from a low of $0.6322 (Jul 22, 2026) to a high of $1.1932 (Aug 11, 2021), with a median of $0.9288 per EA.

Are there cheaper alternatives to BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET (NDC 42858060203) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.